Basic Information
| LncRNA/CircRNA Name | FLJ22447 |
| Synonyms | LncRNA-CAF |
| Region | GRCh38_14:61570540-61654713 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | oral squamous cell carcinoma |
| ICD-0-3 | C06.9 |
| Methods | RNA-seq, qPCR, RIP |
| Sample | breast cancer tissues, cell lines (HSC-3) |
| Expression Pattern | up-regulated |
| Function Description | lncRNA FLJ22447, which was remarkably up-regulated in CAFs, referred to LncRNA-CAF (Lnc-CAF) hereafter. Interleukin-33 (IL-33) was mainly located in the stroma and positively co-expressed with Lnc-CAF to elevate the expression of CAF markers (a-SMA, vimentin and N-cadherin) in fibroblasts. In a co-culture system, IL-33 knockdown impaired Lnc-CAF-mediated stromal fibroblast activation, leading to decreased proliferation of tumor cells. Mechanistically, Lnc-CAF up-regulated IL-33 levels and prevented p62-dependent autophagy-lysosome degradation of IL-33, which was independent of LncRNA-protein scaffold effects. Treatment with the autophagy inducer, rapamycin, impaired the proliferative effect of Lnc-CAF/IL-33 by promoting IL-33 degradation. In turn, tumor cells further increased Lnc-CAF levels in stromal fibroblasts via exosomal Lnc-CAF. |
| Pubmed ID | 29346528 |
| Year | 2018 |
| Title | A novel stromal lncRNA signature reprograms fibroblasts to promote the growth of oral squamous cell carcinoma via LncRNA-CAF/interleukin-33. |
External Links
| Links for FLJ22447 | GenBank HGNC NONCODE |
| Links for oral squamous cell carcinoma | OMIM COSMIC |